Apogee Therapeutics (APGE)
NASDAQ:APGE
Want to see APGE full AI Analyst Report?
Total Valuation
Apogee Therapeutics has a market cap or net worth of $6.24B. The enterprise value is $4.47B.
Market Cap$6.24B
Enterprise Value$4.47B
Share Statistics
Apogee Therapeutics has 61,853,252 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding61,853,252
Owned by Insiders5.97%
Owned by Institutions0.60%
Financial Efficiency
Apogee Therapeutics’s return on equity (ROE) is -0.28 and return on invested capital (ROIC) is -31.29%.
Return on Equity (ROE)-0.28
Return on Assets (ROA)-0.27
Return on Invested Capital (ROIC)-31.29%
Return on Capital Employed (ROCE)-0.31
Revenue Per Employee0.00
Profits Per Employee-1.31M
Employee Count196
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Apogee Therapeutics is ―. Apogee Therapeutics’s PEG ratio is -0.64.
PE Ratio―
PS Ratio0.00
PB Ratio5.07
Price to Fair Value5.07
Price to FCF-19.69
Price to Operating Cash Flow-21.55
PEG Ratio-0.64
Income Statement
In the last 12 months, Apogee Therapeutics had revenue of 0.00 and earned -255.84M in profits. Earnings per share was -4.22.
Revenue0.00
Gross Profit-1.42M
Operating Income-285.60M
Pretax Income-255.56M
Net Income-255.84M
EBITDA-284.18M
Earnings Per Share (EPS)-4.22
Cash Flow
In the last 12 months, operating cash flow was -227.45M and capital expenditures -5.15M, giving a free cash flow of -232.60M billion.
Operating Cash Flow-227.45M
Free Cash Flow-232.60M
Free Cash Flow per Share-3.76
Dividends & Yields
Apogee Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.07
52-Week Price Change106.61%
50-Day Moving Average74.81
200-Day Moving Average59.50
Relative Strength Index (RSI)73.62
Average Volume (3m)1.06M
Important Dates
Apogee Therapeutics upcoming earnings date is May 18, 2026, Before Open (Confirmed).
Last Earnings DateMar 2, 2026
Next Earnings DateMay 18, 2026
Ex-Dividend Date―
Financial Position
Apogee Therapeutics as a current ratio of 26.57, with Debt / Equity ratio of 0.98%
Current Ratio26.57
Quick Ratio26.57
Debt to Market Cap<0.01
Net Debt to EBITDA0.43
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Apogee Therapeutics has paid 278.00K in taxes.
Income Tax278.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Apogee Therapeutics EV to EBITDA ratio is -15.69, with an EV/FCF ratio of -19.17.
EV to Sales0.00
EV to EBITDA-15.69
EV to Free Cash Flow-19.17
EV to Operating Cash Flow-19.60
Balance Sheet
Apogee Therapeutics has $730.19M in cash and marketable securities with $8.85M in debt, giving a net cash position of $721.34M billion.
Cash & Marketable Securities$730.19M
Total Debt$8.85M
Net Cash$721.34M
Net Cash Per Share$11.66
Tangible Book Value Per Share$14.89
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Apogee Therapeutics is $122.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$122.25
Price Target Upside32.59% Upside
Analyst ConsensusStrong Buy
Analyst Count15
Revenue Growth Forecast―
EPS Growth Forecast-30.45%